Phase 3 data on BRAF and MEK combos for melanoma
Interviewed by Steven E. Greer, MD
We have previously reported on Phase 2 data indicating that the combination of a BRAF and MEK inhibitor drug is more effective than BRAF-alone at treating advanced melanoma with BRAF mutations. Phase 3 data are now published, and Dr. Antoni Ribas of UCLA updates us.
NEJM, Oncology, UCLA Med Ctr | apples49 | 
January 9, 2015 3:14 pm
